Status and phase
Conditions
Treatments
About
The study objective was to determine whether liver injury develops in alcoholic patients who ingest therapeutic doses of APAP for three consecutive days. Volunteers were recruited from two community detoxification centers to take either acetaminophen (4 g/day) or placebo for 3 consecutive days and remain in the facility an additional 2 days for monitoring. The primary measures were aminotransferase measures taken at baseline and Days 2-5. We hypothesized that there would be no difference in aminotransferase measures between the acetaminophen and placebo study groups.
Sex
Ages
Volunteers
Inclusion and exclusion criteria
Inclusion Criteria
Any patient, regardless of gender or ethnicity, who was:
Patients were excluded from the study at baseline if any of the following were present:
Loading...
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal